Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,947 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at $2,935,004.98. This represents a 20.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00.

Oruka Therapeutics Stock Down 3.9%

Shares of ORKA stock traded down $3.73 during trading on Tuesday, reaching $92.20. The company’s stock had a trading volume of 784,617 shares, compared to its average volume of 741,278. Oruka Therapeutics, Inc. has a one year low of $14.66 and a one year high of $115.51. The business has a fifty day moving average price of $95.87 and a 200-day moving average price of $72.78. The company has a market cap of $6.10 billion, a price-to-earnings ratio of -45.42 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nykredit A S bought a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $29,000. Orion Capital Management LLC acquired a new position in Oruka Therapeutics during the second quarter valued at approximately $91,000. Natural Investments LLC acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at $202,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth $211,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ORKA has been the subject of several recent research reports. UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Wedbush reissued an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.